(Hypertension. 2000;36:423.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Department of Physiological Science (C.K.R., R.J.B.), University of California, Los Angeles, and the Division of Nephrology and Hypertension (N.D.V., X.Q.W.), Department of Medicine, University of California, Irvine.
Correspondence to R. James Barnard, PhD, Department of Physiological Science, UCLA, PO Box 951527, Los Angeles, CA 90095-1527. E-mail jbarnard{at}ucla.edu
| Abstract |
|---|
|
|
|---|
-nitro-L-arginine
methyl ester (L-NAME) compared with the LFCC diet
group, which showed a marked hypertensive response to
L-NAME. L-NAMEinduced HTN
was reversible with L-arginine in the LFCC diet
group; however, HTN was not corrected by
L-arginine supplementation in the HFS diet group.
These findings point to enhanced ROS-mediated inactivation and
sequestration of NO, which may contribute to the reduction of bioactive
NO and HTN in the HFS dietfed animals.
Key Words: arginine endothelial free radicals insulin resistance L-NAME nitric oxide
| Introduction |
|---|
|
|
|---|
The vascular endothelium is responsible for the production of several vasoactive substances, 1 of the most vital of which is nitric oxide (NO), a potent vasodilator synthesized from L-arginine by the enzyme NO synthase (NOS). Several investigations have demonstrated that endothelium-dependent relaxation is impaired in patients with essential HTN.2 This endothelial dysfunction could be the result of a decrease in biologically active NO, ultimately leading to a depressor/pressor imbalance stemming from tonic removal of NO-mediated vasodilation.2 3
There is evidence that hyperlipidemia4 and high-sugar diets,5 high-fat diets,6 or both induce oxidative stress. We have recently demonstrated increased lipid peroxidation7 and subsequently found direct evidence of NO oxidation by reactive oxygen species (ROS) in a model of lead-induced HTN.8 In addition, we recently reported that female and male rats raised on a high-fat, refined-carbohydrate (HFS) diet developed HTN and endothelial dysfunction.9 10 The present study was designed to test the hypothesis that diet-induced HTN is characterized by enhanced NO oxidation by ROS. To this end, we determined tissue nitrotyrosine (NT), the "footprint" of NO-ROS interaction in rats with HFS dietinduced HTN and compared the results with those obtained in the control low-fat, complex-carbohydrate (LFCC) dietfed animals.
| Methods |
|---|
|
|
|---|
40% kcal); carbohydrate
was from sucrose (
40% kcal). In the LFCC diet, 68% of kcal were
from cornstarch and
10% kcal, from corn oil. Vitamin-free casein
was used for protein. Sodium intakes were lower on the HFS diet because
the rats consumed less food to normalize energy intake. At the various
time points, animals were anesthetized with chloral hydrate
(250 mg/kg IP), and all of the tissues required for further
analyses were excised. The rats were weighed each month.
Blood Pressure
Systolic blood pressure was measured by the tail-cuff
method as previously described.9
L-NAME Studies
Once HTN was established in the HFS diet group,
N
-nitro-L-arginine
methyl ester (L-NAME, Sigma Chemical) was added
to the drinking water in a concentration of 0.5 mg/mL for 1
day,11 and subsequently the blood pressure was
measured. The LFCC dietfed rats were also given
L-arginine (Sigma Chemical, 5 mg/mL in drinking water for 1
day) along with the L-NAME, and blood pressure was
subsequently measured. The HFS dietfed rats were given only
L-arginine at concentrations of 5 or 15 mg/mL for 1 day,
and the blood pressure was again measured.
Urinary NO Metabolite Excretion (Nitrate and Nitrite)
The rats were fasted (but water was provided ad libitum) and
placed into metabolic chambers for 2 days, and urine was
collected and frozen until urinalyses were performed. NO metabolites
were measured by first injecting the urine into a reflux flask
containing 1% vanadium(III)chloride in 2N HCl sparged with
N2. At a boiling temperature of 110°C, the
reflux solution reduces both nitrite and nitrate
(NOx) in the urine back to NO gas. The NO was
drawn through a Dasibi model 2108 chemiluminescence NO
analyzer, where it was reacted with ozone to emit photons that
were detected by a photomultiplier tube. The area under the voltage
peak was integrated (HP 3396 series II integrator) and converted into
total
NO2-+NO3-
concentration. A second urine sample was then injected into an
identical reflux system but with a reflux solution of 1.5% KI in
glacial acetic acid. At a boiling temperature of 98°C, this solution
will reduce only NO2- back to
NO gas. Subtracting this value from the total NOx
value yields the concentrations of
NO3-. Finally, the urine was
analyzed for creatinine by using a
creatinine diagnostic assay kit (Sigma
Chemical). Expressing the NO-to-creatinine ratio
yields the production rate of creatinine, which is
produced at a constant rate; the final results are expressed as
micromoles of NO per milligram of creatinine.
NOS Activity Measurement
Total NOS activity of both diet groups was assessed at 6 months
and 2 years by measuring the conversion of
[3H]arginine to
[3H]citrulline as previously described by
Kobzik et al.12 Frozen renal tissues were
homogenized with a Polytron homogenizer in
4 volumes of a homogenization medium containing
25 mmol/L Tris-HCl (pH 7.4) and 1 mmol/L EDTA. Kidney
homogenates (25 µL) were added to 25 µL of 100 nmol/L
[3H]arginine (50 Ci/mmol) and 100 µL of
reaction buffer containing 50 mmol/L HEPES (pH 7.4), 1 mmol/L
NADPH, 1 mmol/L EDTA, and 1.25 mmol/L
CaCl2. After incubation for 15 minutes at 37°C,
assays were stopped with addition of 2 mL of termination buffer
containing 20 mmol/L HEPES (pH 5.5) and 2 mmol/L EDTA and
placed on ice. Samples were applied to 2-mL columns of Dowex AG50WX-8
(Na+ form) that were eluted with 4 mL of
termination buffer. The eluted [3H]citrulline
was quantified by liquid scintillation spectroscopy.
NT Measurement
Aorta, heart, kidney, and liver tissues (25% wt/vol) from both
the HFS and LFCC diet groups at 2 months and 2 years were
homogenized in a solution containing 50 mmol/L
Tris-HCl (pH 7.4); 1% NP-40; 0.25% sodium deoxycholate; 150
mmol/L NaCl; 1 mmol/L EGTA; aprotinin, leupeptin, and pepstatin (1
µg/mL each); 1 mmol/L
Na3VO4; and 1 mmol/L
NaF at 0°C to 4°C in a Polytron homogenizer.
Homogenates were centrifuged at 12 000g
at 4°C for 5 minutes to remove tissue debris and nuclear fragments.
The supernatant was processed for determination of NT abundance by
Western blot analysis and for total protein concentration by a
bicinchoninic acid protein assay kit (Pierce Inc). Tissue NT
abundance (with 100 µg of protein) was determined by Western blotting
as previously described8 with the use of an anti-NT
monoclonal antibody (Upstate Biotechnology Inc).
Statistical Analysis
Data were analyzed with an ANOVA or t test.
When significant F values were noted, post hoc analyses were
performed with a Newman-Keuls multiple comparison test. Differences
were considered statistically significant at P<0.05. Values
reported are mean±SEM with 7 or 8 rats per group unless otherwise
indicated.
| Results |
|---|
|
|
|---|
|
Response to L-NAME and L-Arginine
When the NOS inhibitor L-NAME was added to
the drinking water (0.5 mg/mL), blood pressure increased significantly
(P<0.005) in the LFCC dietfed rats but was unchanged in
the HFS dietfed rats (Figure 1B). The LFCC rats were then
treated with both L-NAME and
L-arginine (5 mg/mL), and blood pressure was
significantly reduced, from 150.0±6.7 to 132.8±2.7 mm Hg
(P<0.01). The addition of L-arginine
alone to the drinking water had no effect on the HFS rats at 5 mg/mL
(151.8±4.6 mm Hg) and 15 mg/mL (161.0± 7.9 mm Hg).
Differences in blood pressure response could not be explained by
differences in drug intake, since both groups had similar water intakes
that served as the vehicle for drug delivery.
NO Metabolite Excretion
Urine was collected for 2 days at 6 months and 2 years from
animals that were temporarily placed in metabolic chambers,
and analyses were performed for both NO metabolites and
creatinine. Creatinine output was not
significantly different between the 2 groups at either time point. When
the NO metabolites were expressed per milligram of
creatinine, there was no difference in
NOx excretion
(NO2- and
NO3-) in the HFS group compared
with the LFCC group at 6 months (0.38±0.06 versus 0.34±0.12
µmol/mg creatinine). However, at 2 years there was a
marked reduction in urinary NOx excretion
(0.54±0.17 versus 0.01±0.01 µmol/mg creatinine,
P<0.05).
NOS Activity
NOS activity was measured at 6 months and 2 years in renal tissue.
The NOS activity was significantly elevated at 6 months in the HFS diet
group compared with the LFCC diet group (42.05±1.12 versus 29.74±2.35
pmol/mg, P<0.05). However, at 2 years the NOS activity in
the HFS animals was not significantly different from that found in the
LFCC group (31.77±2.58 versus 29.75±2.36 pmol/mg) but was
significantly reduced from the 6-month value.
Nitrotyrosine
Compared with the LFCC rats, the HFS animals exhibited a marked
increase in NT abundance in the aorta (Figure 2), kidney (Figure 3), heart (Figure 4), and liver (Figure 5) at 2 months and 2 years.
|
|
|
|
| Discussion |
|---|
|
|
|---|
NO-dependent vasodilation is reportedly attenuated in patients with
long-standing HTN, as evidenced by a diminished response to
administration of NOS inhibitors.2 The results
of the present study with the NOS inhibitor
L-NAME are consistent with the latter reports.
Administration of L-NAME resulted in a marked rise in blood
pressure in the LFCC dietfed rats to a level that was comparable to
the basal value in the HFS animals. In contrast, blood pressure did not
change with L-NAME administration in the HFS group.
These results corroborate previous evidence that
N
-monomethyl-L-arginine
markedly increases blood pressure in healthy individuals but not in
hypertensive patients.2 14 Furthermore, the lack of a
rise in blood pressure with L-NAME treatment in the
HFS group was not due to a ceiling effect, as rat strains can exhibit
blood pressures exceeding 180 mm Hg.15 Taken
together, the data point to impaired NO availability for vasodilation
in rats maintained on the HFS diet, which we have previously shown to
cause endothelial dysfunction.10
To investigate L-arginine depletion as a possible cause of
the reduction in NOx in the HFS diet group, the
diet was supplemented with L-arginine.
L-Arginine (5 mg/mL) supplementation abrogated the
L-NAMEinduced elevation of blood pressure in the LFCC
group. However, L-arginine supplementation (2 different
dosages) had no effect on HFS dietinduced HTN. These findings exclude
substrate deficiency as a cause of the associated HTN and reduced NO
availability in the HFS dietfed animals. These data are in agreement
with previous studies investigating the effects of exogenous arginine
administration in HTN induced by chronic NOS inhibition.16
Normally, NO generation by NOS is not sensitive to substrate
concentration because the Km of NOS
(
3 µmol/L) is well below the normal concentration of
L-arginine.17 The present
data suggest that L-arginine depletion was not a factor in
the pathogenesis of HFS dietinduced HTN, although absorption of the
arginine supplement was not determined. There is, however, no evidence
of defective amino acid absorption in HTN.
Various ROS, ie, superoxide, hydrogen peroxide, and hydroxyl radical, can inactivate NO. For example, superoxide combines with NO to produce peroxynitrite (ONOO-), a potent cytotoxic reactive nitrogen species that subsequently reacts with proteins, lipids, and DNA to induce tissue damage.18 ONOO- reacts with tyrosine residues to produce NT, a stable footprint of NO oxidation by ROS that can be detected in tissues. In addition, ROS can react with tyrosine to produce tyrosyl radicals, which can oxidize NO to generate NT.19 Consequently, nitration of tyrosine residues can be used as a surrogate measure for ROS-mediated inactivation of NO. The elevation of NT abundance in various tissues of the HFS dietfed group is tangible evidence for the presence of oxidative stress leading to enhanced NO inactivation and sequestration in tissues. Increased accumulation of NT in various tissues has been recently documented in lead-induced HTN,8 which is marked by increased ROS.7 This phenomenon contributes to HTN by limiting NO availability to vascular smooth muscle, causing vasoconstriction, and to renal tubular epithelial cells, causing sodium retention.
Accumulation of NT and hence, enhanced ROS-mediated inactivation of NO, was evident as early as 2 months after consumption of the HFS diet. This change was accompanied by a compensatory increase in the NOS activity that was evident at 6 months. We have recently shown a marked increase in inactivation of NO by ROS in rats with lead-induced HTN.8 This was associated with a significant fall in urinary NOx excretion and a compensatory upregulation of NOS isotype expression in these animals.20 The upregulation of NOS isotypes in the latter studies was due to ROS-mediated reduction of available NO, which has been shown to exert a negative-feedback influence on NOS protein expression.21 Despite enhanced NO inactivation and sequestration, urinary NOx excretion was normal and blood pressure was mildly elevated during the first 6 months on the HFS diet. These adaptive changes noted early in the course of feeding the HFS diet to young animals can in part be due to the observed increase in NOS activity and perhaps sufficient natural antioxidant capacity. However, with long-term HFS diet consumption, the urinary NOx excretion fell and blood pressure rose significantly, denoting a progressive decline in the animals capacity to overcome the effects of the HFS diet.
It should be noted that by diverting NO to reactive nitrogen species, protein nitration can contribute to an initial decline in NOx generation and its urinary excretion. However, isomerization of ONOO- and turnover of NT and other nitrated products to nitrate and nitrite will ultimately raise NOx production and its urinary excretion to a level approximating the rate of NO generation. Thus, the fall in urinary NOx excretion observed in rats consuming the HFS diet during the chronic phase is a strong indicator of reduced NO production. This viewpoint is supported by the observation that NOS activity, which was elevated in the early phase, fell significantly in the late phase of HFS diet consumption. The reduction of NOS activity may be due to a quantitative deficiency and/or a depressed activity of the enzyme. We wish to acknowledge that there exist alternative pathways other than NOS by which citrulline may be generated in tissues.22 Although we did not measure the NOS-inhibitable fraction of citrulline generation in our assay, we have recently documented an increase in the immunodetectable levels of NOS that parallels the functional data reported here (C.K.R. et al, unpublished data, 2000). The constellation of HTN, decreased urinary NOx excretion, and increased tissue NT abundance found in the HFS dietfed animals herein closely resembles the earlier findings in animals with lead-induced HTN.8 21 The sources of the NO recovered in the urine as NOx are not known, as NOS is present in many cell types. Nevertheless, the reduction in urinary NOx excretion in the aged, hypertensive, HFS animals is indicative of depressed NO availability in this model. This observation is consistent with earlier reports that have demonstrated a decrease in bioactive NO in hypertensive humans.23
Böger et al24 have suggested several potential mechanisms that could explain the impaired biological activity of the NO pathway observed in HTN, including (1) defective L-arginine availability, (2) decreased expression or activity of the NOS enzymes, and (3) increased oxidative degradation of NO. The present data appear to rule out an L-arginine deficiency. However, our data suggest that the decrease in biologically active NO may be related to enhanced oxidative scavenging and inactivation of NO. Our previous data,20 25 as well as that of others,26 suggest that NOS isotype expression paradoxically increases in some forms of HTN. Additionally, the decrease in total renal NOS activity at 2 years compared with 6 months in the HFS group may be due to NOS inhibition, possibly by an endogenous NOS inhibitor such as asymmetric dimethylarginine,27 which has been demonstrated to be elevated in hypertensive patients,28 or alternatively, due to cofactor depletion by ROS.29 These factors, as well as enzymatic inactivation due to oxidative damage, may contribute to the decrease in NOS activity coincident with the reduction in NOx excretion noted later in this model. The persistent elevation of NT abundance may appear to conflict with the declining NO production in the chronic phase of the HFS diet; however, a greater proportion of NO produced during this period appears to have been consumed by ROS-mediated inactivation and sequestration processes, which sustained the elevated NT burden while virtually exhausting the bioactive NO. The latter contention is supported by the lack of a pressor response to L-NAME in the HFS diet group, indicating a virtual absence of NO-mediated vasodilatory tone. Accordingly, massive diversion of NO was sufficient to maintain the elevation in NT abundance despite an overall reduction in total-body NO production.
The rise in blood pressure on the HFS diet was a slow and gradual process. However, metabolic abnormalities appeared quite early. For instance, insulin resistance and hyperinsulinemia have been previously demonstrated within 2 weeks,9 and hypertriglyceridemia, which is associated with endothelial dysfunction, is observed at 2 months, well before the development of significant HTN.9 In addition to the compensatory responses noted earlier, during the early phase of the study the protective effects of estrogen as an antioxidant and a vasodilator (acting via NOS) may have helped retard HTN in the young female rats.30 The observation that significant HTN was not noted in the HFS rats until they had been on the diet for 18 months and were at a "postmenopausal" age supports this contention. A similar pattern has been observed in women in this country, in whom HTN is generally not seen until after menopause, and suggests that this dietary paradigm may be applicable to human HTN.
The precise mechanism by which the HFS diet induced oxidative stress in our animals is not clear. However recent evidence suggests that high-sugar,5 29 high-fat,6 and high-cholesterol31 diets increase free radical production. In addition, the high sucrose content of the HFS diet causes postprandial hyperglycemia, which has been recently demonstrated to increase the generation of superoxide in human endothelial cells.32 These in vitro findings are consistent with the present data that show an initial elevation in NOS activity and ROS-mediated increase in NT abundance in rats on the HFS diet. Furthermore, the role of ROS in the pathogenesis of HTN has been substantiated in a recent study by Vaziri et al,33 who demonstrated the occurrence of severe, sustained HTN with the induction of oxidative stress by glutathione depletion in normotensive rats.
Overall, this study has demonstrated the presence of oxidative stress and inactivation of NO in rats maintained on the HFS diet, which may contribute to the development of HTN. Further work is needed to establish whether or not insulin resistance/hyperinsulinemia, obesity, or both are directly involved in the mechanism of diet-induced HTN or whether these conditions are simply another independent manifestation of the high-fat, refined-carbohydrate diet typically consumed in westernized societies. Finally, whether or not antioxidant therapy can affect HFS dietinduced HTN remains to be studied.
| Acknowledgments |
|---|
Received January 20, 2000; first decision February 8, 2000; accepted March 15, 2000.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
E. Jebelovszki, C. Kiraly, N. Erdei, A. Feher, E. T. Pasztor, I. Rutkai, T. Forster, I. Edes, A. Koller, and Z. Bagi High-fat diet-induced obesity leads to increased NO sensitivity of rat coronary arterioles: role of soluble guanylate cyclase activation Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2558 - H2564. [Abstract] [Full Text] [PDF] |
||||
![]() |
R J. Barnard Prostate cancer prevention by nutritional means to alleviate metabolic syndrome Am. J. Clinical Nutrition, September 1, 2007; 86(3): 889S - 893S. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rodriguez-Iturbe, L. Sepassi, Y. Quiroz, Z. Ni, and N. D. Vaziri Association of mitochondrial SOD deficiency with salt-sensitive hypertension and accelerated renal senescence J Appl Physiol, January 1, 2007; 102(1): 255 - 260. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.P. Webster, D. Brockman, and L. Myatt Nitration of p38 MAPK in the placenta: association of nitration with reduced catalytic activity of p38 MAPK in pre-eclampsia Mol. Hum. Reprod., November 1, 2006; 12(11): 677 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Erdei, A. Toth, E. T. Pasztor, Z. Papp, I. Edes, A. Koller, and Z. Bagi High-fat diet-induced reduction in nitric oxide-dependent arteriolar dilation in rats: role of xanthine oxidase-derived superoxide anion Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2107 - H2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Smith, M. W. Brands, M.-H. Wang, and A. M. Dorrance Obesity-induced hypertension develops in young rats independently of the Renin-Angiotensin-aldosterone system. Experimental Biology and Medicine, March 1, 2006; 231(3): 282 - 287. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Roberts, R. J. Barnard, R. K. Sindhu, M. Jurczak, A. Ehdaie, and N. D. Vaziri A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression J Appl Physiol, January 1, 2005; 98(1): 203 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Barnard Prevention of Cancer Through Lifestyle Changes Evid. Based Complement. Altern. Med., December 1, 2004; 1(3): 233 - 239. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rodriguez-Iturbe, N. D. Vaziri, J. Herrera-Acosta, and R. J. Johnson Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all Am J Physiol Renal Physiol, April 1, 2004; 286(4): F606 - F616. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Roberts, N. D. Vaziri, R. K. Sindhu, and R. J. Barnard A high-fat, refined-carbohydrate diet affects renal NO synthase protein expression and salt sensitivity J Appl Physiol, March 1, 2003; 94(3): 941 - 946. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rodriguez-Iturbe, C.-D. Zhan, Y. Quiroz, R. K. Sindhu, and N. D. Vaziri Antioxidant-Rich Diet Relieves Hypertension and Reduces Renal Immune Infiltration in Spontaneously Hypertensive Rats Hypertension, February 1, 2003; 41(2): 341 - 346. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Roberts, N. D. Vaziri, and R. J. Barnard Effect of Diet and Exercise Intervention on Blood Pressure, Insulin, Oxidative Stress, and Nitric Oxide Availability Circulation, November 12, 2002; 106(20): 2530 - 2532. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nasreen, T. Nabika, H. Shibata, H. Moriyama, K. Yamashita, J. Masuda, and S. Kobayashi T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers: Possible Gene-Environmental Interaction Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 605 - 610. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. J. Zhou, N. D. Vaziri, X. Q. Wang, F. G. Silva, and Z. Laszik Nitric Oxide Synthase Expression in Hypertension Induced by Inhibition of Glutathione Synthase J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 762 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Vaziri, Z. Ni, F. Oveisi, K. Liang, and R. Pandian Enhanced Nitric Oxide Inactivation and Protein Nitration by Reactive Oxygen Species in Renal Insufficiency Hypertension, January 1, 2002; 39(1): 135 - 141. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Roberts, N. D. Vaziri, and R. J. Barnard Protective effects of estrogen on gender-specific development of diet-induced hypertension J Appl Physiol, November 1, 2001; 91(5): 2005 - 2009. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Dobrian, S. D. Schriver, and R. L. Prewitt Role of Angiotensin II and Free Radicals in Blood Pressure Regulation in a Rat Model of Renal Hypertension Hypertension, September 1, 2001; 38(3): 361 - 366. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Vaziri, Y. Ding, and Z. Ni Compensatory Up-Regulation of Nitric-Oxide Synthase Isoforms in Lead-Induced Hypertension; Reversal by a Superoxide Dismutase-Mimetic Drug J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 679 - 685. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. K. Roberts, N. D. Vaziri, K. H. Liang, and R. J. Barnard Reversibility of Chronic Experimental Syndrome X by Diet Modification Hypertension, May 1, 2001; 37(5): 1323 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Vaziri, Z. Ni, F. Oveisi, and D. L. Trnavsky-Hobbs Effect of Antioxidant Therapy on Blood Pressure and NO Synthase Expression in Hypertensive Rats Hypertension, December 1, 2000; 36(6): 957 - 964. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Nasreen, T. Nabika, H. Shibata, H. Moriyama, K. Yamashita, J. Masuda, and S. Kobayashi T-786C Polymorphism in Endothelial NO Synthase Gene Affects Cerebral Circulation in Smokers: Possible Gene-Environmental Interaction Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 605 - 610. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||